Buy tech sell-off, Wedbush’s Ives says: ’this is a 1996 moment, not 1999’
DUBLIN - Investment giant BlackRock, Inc. has disclosed a 1.64% stake in Mural Oncology plc, according to a regulatory filing published Monday.
The disclosure, made under Irish Takeover Panel rules, reveals that BlackRock holds 284,295 shares in the oncology-focused company as of September 26, 2025. This position includes 284,280 owned and controlled relevant securities and 15 shares through cash-settled derivatives.
The filing shows BlackRock purchased 4,665 Mural Oncology shares at a price of $2.0859 per unit in its most recent transaction.
The disclosure was made in compliance with Rule 8.3 of the Irish Takeover Panel Act, which requires persons with interests in relevant securities representing 1% or more to disclose their positions.
The filing indicates BlackRock holds no short positions in Mural Oncology securities and has not engaged in any stock-settled derivative transactions involving the company’s shares.
According to the disclosure, there are no indemnity arrangements, agreements, or understandings relating to options or derivatives between BlackRock and any other parties.
The information was submitted through a Form 8.3 filing, which is required when a company may be involved in a takeover situation, though no specific offer details were mentioned in the disclosure.
The regulatory filing was submitted to the Regulatory Information Service as required under Irish takeover rules.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.